In contrast, despite evidence from some animal models that IL-17 is implicated in pathogenesis, a trial in Crohn’s disease of secukinumab, a fully human anti-IL-17 monoclonal antibody, was terminated early as it was ineffective with an excess of adverse events [48]. Here, IL17A is linked to Crohn disease.